Skip to main content Back to Top
Advertisement

2/27/2017

Potassium Acetate Injection

Products Affected - Description

    • Potassium acetate injection, American Regent, 2 mEq/mL, 20 mL vial, 25 count, NDC 00517-2053-25
    • Potassium acetate injection, American Regent, 4 mEq/mL, 50 mL vial, 25 count, NDC 00517-5024-25

Reason for the Shortage

    • American Regent has potassium acetate on long-term shortage due to manufacturing delays. It is unclear if and when product will return to market
    • Pfizer has potassium acetate injection available.
    • Exela received FDA approval for potassium acetate injection in late-December 2015. Exela has potassium acetate injection available.

Available Products

    • Potassium acetate injection, Exela Pharma Sciences, 2 mEq/mL, 20 mL vial, 25 count, NDC 51754-2001-04
    • Potassium acetate injection, Pfizer, 2 mEq/mL, 20 mL vial, 25 count, NDC 00409-8183-01
    • Potassium acetate injection, Pfizer, 2 mEq/mL, 50 mL vial, 25 count, NDC 00409-3924-51

Estimated Resupply Dates

    • American Regent has potassium acetate 2 mEq/mL 20 mL vials and 4 mEq/mL 50 mL vials on long-term back order and the company cannot estimate a release date.
    • All other marketed presentations are available.

Updated

Updated February 27, 2017 by Michelle Wheeler, PharmD, Drug Information Specialist. Created December 30, 2015 by Michelle Wheeler, PharmD, Drug Information Specialist. Copyright 2017, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.